

Dispelling the myths: HIV, ageing and the changing causes of morbidity

Caroline A Sabin

Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), UCL, London, UK




Disclosures

I have received funding for membership of Data Safety and Monitoring Boards, Advisory Boards, Speaker Panels and for preparation of educational materials from the following:

- Gilead Sciences
- ViiV Healthcare
- Janssen-Cilag




Age of UK CHIC participants






Future projections






Future projections



Smit M et al. Lancet Infect Dis 2015;15:e810-18.




Future projections




Smit M et al. Lancet Infect Dis 2015;15:e810-18.

Reported prevalence of common co-morbidities




Age vs. number of common co-morbidities





Co-morbidities



Mean number of comorbidities:

HIV-positive: 1.3 HIV-negative: 1.0

Raised rates of:

Hypertension MI Peripheral arterial disease

Impaired renal function





 Literature abundant with studies reporting that HIV causes 'premature ageing' or that co-morbidities occur at an earlier age in PLWH



 Literature abundant with studies reporting that HIV causes 'premature ageing' or that co-morbidities occur at an earlier age in PLWH





 Literature abundant with studies reporting that HIV causes 'premature ageing' or that co-morbidities occur at an earlier age in PLWH





- Literature abundant with studies reporting that HIV causes 'premature ageing' or that co-morbidities occur at an earlier age in PLWH
- Search continues for biological mechanisms that drive this apparent increased risk
 - Residual inflammaton / 'Inflammageing'?
 - Altered gut microbiota?
 - Mitochondrial dysfunction?
 - Immunosenescence?



 Literature abundant with studies reporting that HIV causes 'premature ageing' or that co-morbidities occur at an earlier age in PLWH

In our rush to establish mechanisms, have we forgotten the basic rules of epidemiology?

- Nesidual illiammatom / illiammayemy
- Altered gut microbiota?
- Mitochondrial dysfunction?
- Immunosenescence?



Confounding

- PLWH have very different characteristics to the general population, including increased risk of:
 - sexually transmitted infections
 - viral coinfections
 - smoking
 - recreational drug use, etc.
- Could these other factors confound associations with comorbidities and/or bio-markers?



Bias due to confounding


Occurs when a spurious association arises (or is hidden)
due to a failure to fully adjust for factors related to both the
risk factor and outcome

HIV Co-morbidity



Bias due to confounding


 Occurs when a spurious association arises (or is hidden) due to a failure to fully adjust for factors related to both the risk factor and outcome






Bias due to confounding

 Occurs when a spurious association arises (or is hidden) due to a failure to fully adjust for factors related to both the risk factor and outcome





Co-morbidities are often multi-factorial





Confounding


- PLWH have very different characteristics to the general population, including increased risk of:
 - sexually transmitted infections

Does HIV really cause premature ageing – or is this simply a result of unmeasured confounding?

 Could these other factors confound associations with co-morbidities and/or bio-markers?



What is being said?




PWH develop comorbidities 10-15 years younger than people without HIV

HIV is causing accelerated ageing




What is being said?





Causes of death








Deaths from cancer - Mortalité surveys

	Mortalité 2000	Mortalité 2005	Mortalité 2010	p-value
Reported deaths	964	1042	728	
Cancer-related causes of death, n (%)	269 (27.9%)	344 (33.0%)	262 (36.0%)	0.003
AIDS-related, n (%)	149 (15.5%)	134 (12.9%)	68 (9.3%)	0.024
Non Hodgkin lymphoma	105 (10.9%)	103 (9.9%)	53 (7.3%) ^b	0.122
Kaposi sarcoma	40 (4.1%)	25 (2.4%)	11 (1.5%)	0.084
Cervical cancer	4 (0.4%)	6 (0.6%)	4 (0.5%)	0.848
Hepatitis-related, n (%)	17 (1.8%)	37 (3.6%)	31 (4.3%)	0.028
Hepatitis C	8 (0.8%)	27 (2.6%)	19 (2.6%)	0.021
Hepatitis B	7 (0.7%)	6 (0.6%)	10 (1.4%)	0.279
Hepatitis B and C	2 (0.2%)	4 (0.4%)	2 (0.3%)	0.732
Non AIDS/non hepatitis related, n (%)	103 (10.7%)	173 (16.6%)	163 (22.4%)	<0.001
Respiratory	50 (5.2%)	65 (6.2%)	78 (10.7%)	0.004
Lung	44 (4.6%)	53 (5.1%)	61 (8.4%)	0.040
Ear, nose and throat	6 (0.6%)	12 (1.2%)	17 (2.3%)	0.056
Digestive	6 (0.6%)	13 (1.2%)	10 (1.4%)	0.342
Pancreas	3 (0.3%)	11 (1.1%)	7 (1.0%)	0.282
Anal	6 (0.6%)	11 (1.1%)	13 (1.8%)	0.073
Skin	2 (0.2%)	10 (1.0%)	3 (0.4%)	0.065
Hodgkin's lymphoma	12 (1.2%)	9 (0.9%)	8 (1.1%)	0.473
Other hemopathies	5 (0.5%)	8 (0.8%)	7 (1.0%)	0.602
Breast	3 (0.3%)	7 (0.7%)	5 (0.7%)	0.647
Central nervous system	4 (0.4%)	6 (0.6%)	2 (0.3%)	0.530
Other and unknown ^c	12 (1.2%)	33 (3.2%)	27(3.7%)	0.029
Multiple ^d	-	-	3 (0.4%)	-

Vandenhende M-A et al. PLoS One 2015; 10(6): e0129550.




Deaths from cancer - Mortalité surveys



Vandenhende M-A et al. *PLoS One* 2015; **10(6)**: e0129550.



Removing a cause of morbidity




Deaths from HIV causes

Deaths from non-HIV causes

40/70 (57.1%) deaths due to non-HIV causes



Removing a cause of morbidity




Deaths from HIV causes

Deaths from non-HIV causes

40/55 (72.7%) deaths due to non-HIV causes



Removing a cause of morbidity




Deaths from HIV causes

Deaths from non-HIV causes

45/60 (75.0%) deaths due to non-HIV causes



Age-standardised mortality rates








Non-AIDS mortality after HIV diagnosis


■ In 1st year ■ After 1st year



Standardised mortality ratio (SMR)




Non-AIDS mortality after HIV diagnosis



Croxford S et al Lancet Pub Health 2017; 2: e35-e46.



What is being said?







CHEST

Commentary

Epidemic of Lung Cancer in Patients With HIV Infection

Tiffany A. Winstone, MD; S. F. Paul Man, MD, FCCP; Mark Hull, MD; Julio S. Montaner, MD, FCCP; and Don D. Sin, MD, FCCP

Several studies have examined the risk of lung cancer in the HIV-infected population (Table 1). Approximately one-half of these studies used a case-control design, whereas the other half used a longitudinal cohort approach. Of note, the average age at lung cancer diagnosis in this population was between 38 and 57 years. In contrast, the average age at lung cancer diagnosis in the general population is approximately 70 years. On a discouraging note, most of the cases were discovered in stages III or IV, and the median survival of these patients was measured in months from the time of diagnosis (Table 1).



CLINICAL SCIENCE


Geriatric Syndromes in Older HIV-Infected Adults

Meredith Greene, MD,*† Kenneth E. Covinsky, MD, MPH,*† Victor Valcour, MD, PhD,*‡
Yinghui Miao, MD, MPH,*† Joy Madamba, BS,§ Harry Lampiris, MD,#|| Irena Stijacic Cenzer, MA,*†


Jeffrey Martin, MD, MPH,¶ and Steven G. Deeks, MD§

In comparison, reported rates of falls and incontinence from the general population of community dwelling adults aged 65 years and older are 30% and 22% (for older men), respectively. Estimates of frailty depend on the definition, but using the Fried phenotype definition, estimates range from 7% (original Fried article) to 10%–14%. These data suggest that HIV-infected adults may experience similar rates of geriatric syndromes at relatively younger ages and emphasize the critical need for appropriate HIV-negative comparison groups to put these findings into further context.











Age at onset of co-morbidity – VACS VC


Event	No. events	Mean age diagnosis	Crude diff.	Adjusted diff.	95% CI		
MI							
HIV-ve	308	56.0	0.2	-0.11	-0.59, +0.37		
HIV+ve	291	56.2					
End-stage renal disease							
HIV-ve	688	59.4	-3.4	-0.46	-0.86, -0.07		
HIV+ve	447	56.0					
NADC							
HIV-ve	2708	58.9	-1.1	-0.10	-0.30, 0.10		
HIV+ve	1471	57.8					
HIV-associated cancers							
HIV-ve	826	58.6	-2.0	-0.22	-0.52, 0.08		
HIV+ve	732	56.6					

Althoff KN et al. Clin Infect Dis 2015;60:627-38.




Bias due to confounding

 Occurs when a spurious association arises (or is hidden) due to a failure to fully adjust for factors related to both the risk factor and outcome






What is being said?





























Sabin CA, Reiss P. AIDS 2017; 31(Suppl 2): S121-S128.











Sabin CA, Reiss P. AIDS 2017; 31(Suppl 2): S121-S128.




Why is this important?

- Underlying aetiology and/or mechanisms differ
- Statistical approach to test for each will differ need to consider the 'slope' of the association with age, as well as absolute risk of event
- Studies that claim to demonstrate 'accelerated' ageing, often provide little evidence to support the statement
- Difficult to differentiate between the models with a crosssectional study

The Co-morBidity in Relation to Aids (COBRA) Collaboration





POPPY:

'Pharmacokinetic and Clinical Observations in People over Fifty'






COBRA: clinical studies run as sub-studies of POPPY and AGE_hIV :

- Collecting the extra information required
- Whilst utilising the existing infrastructure




Neuroimaging results - COBRA



Cole JH et al. Clin Infect Dis 2018; 66: 1899-1909




Cognitive testing results - COBRA



Cole JH et al. Clin Infect Dis 2018; 66: 1899-1909




Bio-marker age advancement - COBRA



De Francesco D et al. AIDS 2018 (in press).



What is being said?







Immunosenescence and HIV



People living with HIV (PLWH) who are treated with effective highly active antiretroviral therapy (HAART) have a similar life expectancy to the general population. Moreover, an increasing proportion of new HIV diagnoses are made in people older than 50 y. The number of older HIV infected patients is thus constantly growing and it is expected that by 2030 around 70% of PLWH will be more than 50 y old. On the other hand, HIV infection itself is responsible for accelerated immunosenescence, a progressive decline of immune system function in both the adaptive and the innate arm, which impairs the ability of an individual to respond to infections and to give rise to long-term immunity; furthermore, older patients tend to have a worse immunological response to HAART.
























	HIV-positive	HIV-negative	Blood-bank donors
N	40	40	35
Age (yrs), median (IQR)	58 (53-63)	59 (53-64)	58 (52-65)
Male sex, %	90	92.5	51.4
African origin, %	12.5	2.5	n/a
MSM, %	80.0	75.0	n/a
CMV+ve, %	95.0	77.5	22.9
Anti-CMV IgG	50.9 (23.5-108.6)	23.9 (13.8-87.8)	11.3 (10.2-16.8)
High avidity anti-CMV IgG	30.7 (13.0-57.0)	13.3 (8.2-39.7)	10.7 (10.0-13.2)

















Bias due to confounding


 Occurs when a spurious association arises (or is hidden) due to a failure to fully adjust for factors related to both the risk factor and outcome





Inflammation markers - SMART


PLWH aged **45-76** years vs. participants in Multi-Ethnic Study of Atherosclerosis (MESA) study



^{*} Fully adjusted model includes adjustment for age, race, sex, BMI, smoking, TC/HDL ratio, diabetes, lipid-lowering drugs, anti-hypertensive drugs




Mortality – FRAM cohort






Risk of death – SMART





Risk of death – SMART





Inflammation markers - SMART

Subset of SMART participants on ART with HIV RNA ≤400 copies/ml

Participants 33–44 years of age			Pa	irticipants 45–76 ye	ars of age
No.	Median level (IQR)	% Diff. (P)	No.	Median level (IQR)	% Diff. <i>(P)</i>
140	2.13 (0.77–5.20)	40.2 (<.001)	293	2.83 (1.07–6.80)	37.8 (<.001)
139	1.89 (1.15-3.42)	39.0 (<.001)	291	2.64 (1.55-4.14)	60.1 (<.001)
140	0.21 (0.15-0.46)	NA	293	0.29 (0.17–0.57)	49.1 (<.001)
86	0.90 (0.78–0.97)	NA	130	1.00 (0.86–1.16)	20.9 (<.001)
	No. 140 139 140	Median No. level (IQR) 140 2.13 (0.77–5.20) 139 1.89 (1.15–3.42) 140 0.21 (0.15–0.46)	Median No. level (IQR) % Diff. (P) 140 2.13 (0.77–5.20) 40.2 (<.001) 139 1.89 (1.15–3.42) 39.0 (<.001) 140 0.21 (0.15–0.46) NA	Median No. level (IQR) % Diff. (P) No. 140 2.13 (0.77–5.20) 40.2 (<.001)	Median No. Median level (IQR) Mo. Median level (IQR) 140 2.13 (0.77–5.20) 40.2 (<.001)

NOTE. Data are the median level and (interquartile range [IQR]). CARDIA, Coronary Artery Development in Young Adults; Diff., difference; MESA, Multi-Ethnic Study of Atherosclerosis; NA, not available; SMART, Strategies for Management of Anti-Retroviral Therapy.



Smoking - AGE_hIV

	hsCRP		D-dimer		
	OR (95% CI)	P-value	OR (95% CI)	P-value	
All participants					
Never smoker	Ref.		Ref.		
Former smoker	1.04 (0.80, 1.35)	0.79	0.92 (0.70, 1.22)	0.57	
Current smoker	1.57 (1.16, 2.12)	0.004	1.36 (1.00, 1.85)	0.05	
HIV-positive status	1.44 (1.13, 1.83)	0.003	0.64 (0.50, 0.83)	0.001	
Current smokers only					
Cigarettes smoked per day (/10)	1.49 (1.18, 1.87)	0.001	1.30 (1.04, 1.63)	0.02	
HIV-positive status	1.24 (0.78, 1.97	0.37	0.52 (0.32, 0.84)	0.007	

Kooij KW, et al. *J Infect Dis* 2016; **214**: 1817-1821



Smoking




Fig. 1. Excess mortality and loss of life years. Age-specific excess mortality rates (a) and numbers of life years lost (b) in association with smoking (black bars/line) and HIV-related factors (grey bars/line) among HIV-infected men. PY, person-years.



Lifestyle factors

- In addition to smoking, several other demographic and lifestyle/behavioural factors are prevalent in PWH
 - Obesity/low exercise levels
 - Recreational drug use
 - Alcohol use
- Each is associated with raised inflammatory markers
- Each is associated with morbidity/mortality risk
- What role do these play?



Summary

- Population of people with HIV is aging:
 - increased incidence and spectrum of age-related comorbidities
 - when people die, increasingly dying of non-AIDS causes
- Partly to be expected, given the age and lifestyle/demographic factors that are prevalent
- Statements about HIV and ageing are often based on poor interpretation of data and/or lack of adjustment for confounders



Summary (2)

- Whilst there may be some effect of HIV, model appears to be one of accentuated rather than accelerated ageing
- Need to focus our efforts on understanding the reasons for this – with a view to identifying appropriate interventions
- But should also continue to focus on other modifiable risk factors, as in the general population



Acknowledgements

- Teresa Hill, Sophie Jose, Margaret May, UK CHIC study team
- Alan Winston, Davide de Francesco, POPPY study team
- Peter Reiss, Jonathan Underwood, Neeltje Kootstra, COBRA team
- Paddy Mallon, Aoife Cotter, Jane O'Halloran, UPBEAT study team
- Colette Smith, Jens Lundgren, Lene Ryom, D:A:D study team